Ascendis Pharma (ASND) SVP discloses warrant and RSU positions

Rhea-AI Filing Summary

Ascendis Pharma A/S executive Mads Bodenhoff, SVP & PAO, reports existing equity-based holdings in the company. He holds warrants over 30,000, 3,117 and 3,687 underlying ordinary shares with exercise prices of 124.5200, 139.6500 and 110.0000, expiring between July 13, 2031 and October 11, 2032, with at least one warrant grant fully vested and currently exercisable.

He also holds restricted stock units covering 2,634, 3,967 and 2,768 underlying ordinary shares, each RSU representing a contingent right to receive one ADS. These RSUs vest on or beginning March 1, 2027, with some grants vesting in two or three equal annual installments and having no expiration date.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bodenhoff Mads

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP DK-2900

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & PAO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	(1)	07/13/2031	Ordinary Shares	30,000	$124.52	D
Warrants	(1)	12/09/2031	Ordinary Shares	3,117	$139.65	D
Warrants	(2)	10/11/2032	Ordinary Shares	3,687	$110	D
Restricted Stock Units	(3)	(3)	Ordinary Shares	2,634	(4)	D
Restricted Stock Units	(5)	(5)	Ordinary Shares	3,967	(4)	D
Restricted Stock Units	(6)	(6)	Ordinary Shares	2,768	(4)	D

Explanation of Responses:

1. The warrants are fully vested and currently exercisable.

2. The warrants vested 25% on October 11, 2023 and thereafter in 36 equal monthly installments.

3. The restricted stock units vest on March 1, 2027 and have no expiration date.

4. Each restricted stock unit represents a contingent right to receive one ADS.

5. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.

6. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

	/s/ Michael Wolff Jensen as attorney-in-fact for Mads Bodenhoff	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider holdings did Ascendis Pharma (ASND) SVP Mads Bodenhoff report?

Mads Bodenhoff reported existing warrant and RSU holdings in Ascendis Pharma. He holds warrants over 30,000, 3,117 and 3,687 underlying ordinary shares, plus restricted stock units over 2,634, 3,967 and 2,768 underlying shares, all reported as directly owned positions.

What warrants does Ascendis Pharma (ASND) SVP Bodenhoff hold?

Bodenhoff holds three series of Ascendis Pharma warrants. They cover 30,000, 3,117 and 3,687 underlying ordinary shares with exercise prices of 124.5200, 139.6500 and 110.0000, expiring on July 13, 2031, December 9, 2031 and October 11, 2032 respectively.

Are any of Ascendis Pharma (ASND) SVP Bodenhoff’s warrants currently exercisable?

At least one of Bodenhoff’s warrant grants is fully vested and currently exercisable. A footnote states that the warrants are fully vested and currently exercisable, while another explains a separate warrant grant vested 25% on October 11, 2023 and continues vesting monthly.

What restricted stock units does Ascendis Pharma (ASND) SVP Bodenhoff hold?

Bodenhoff holds three restricted stock unit grants over Ascendis Pharma ordinary shares. They cover 2,634, 3,967 and 2,768 underlying shares, each RSU representing a contingent right to receive one ADS, with vesting starting on March 1, 2027 in one, two, or three annual installments.

When do Ascendis Pharma (ASND) SVP Bodenhoff’s restricted stock units vest?

The reported restricted stock units vest beginning on March 1, 2027. One grant vests fully on March 1, 2027, another vests in two equal annual installments starting that date, and a third vests in three equal annual installments beginning on the same date.

How many ADSs can Ascendis Pharma (ASND) SVP Bodenhoff receive from his RSUs?

Each of Bodenhoff’s restricted stock units represents one ADS of Ascendis Pharma. He holds RSUs over 2,634, 3,967 and 2,768 underlying ordinary shares, and a footnote specifies that each RSU corresponds to a contingent right to receive one ADS upon vesting.